Nordic Capital's $846-million acquisition of specialty pharmaceutical firm Advanz Pharma

On June 1, 2021, specialty pharmaceutical company Advanz Pharma Corp. Limited announced the completion of its sale to leading European private equity investor Nordic Capital for $846 million.

According to the deal, each Advanz Pharma shareholder will get $17.26 in cash per share of the company. This excludes Bybrook, the former shareholder of the company who opted for the alternative offer and whose shares were swapped for Topco B Shares.